top of page

Psilocybin Therapy for Depression - Clinical Insights

After the release of the first comparison of psilocybin with an SSRI antidepressant, Michelle Baker Jones & Leonie Schneider explain what psilocybin therapy for depression involves.

Leonie was a patient of Michelle in psilodep 1, and together they provide insight into psilocybin therapy from the perspective of both therapist and patient.

Michelle Baker Jones is an integrative psychotherapeutic counsellor at the Centre for Psychedelic Research. She was lead guide on the trial comparing psilocybin to SSRI anti-depressants (escitalopram) as a form of treatment for depression (Psilodep 2).

This webinar was recorded during a FREE Women in Psychedelic Science event which showcased the inspiring work of women in psychedelic research.

To receive updates about the next Women in Psychedelic Science event, join the Drug Science Mailing list.

Drug Science is the leading independent scientific body on drugs in the UK. We rely on donations to provide clear, evidence-based information without political or commercial interference. Drug Science webinars are free, and always will be, so if you’d like to support us then please consider joining the Drug Science Community.

Keep up with developments in drug science

Reading, engaging with, and sharing our publications, papers and commentary gives evidence-based science and policy the audience it needs and deserves.

bottom of page